A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Boehringer Ingelheim
Hoffmann-La Roche
Bristol-Myers Squibb
Taiho Oncology, Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Boehringer Ingelheim
Gilead Sciences
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Inhibrx Biosciences, Inc
Lantern Pharma Inc.
Guangzhou JOYO Pharma Co., Ltd
BeiGene
Merck Sharp & Dohme LLC
Avistone Biotechnology Co., Ltd.
ImmunoGenesis
Bristol-Myers Squibb
Checkpoint Therapeutics, Inc.
Inspirna, Inc.
EpicentRx, Inc.
Blueprint Medicines Corporation
Novartis
Novartis
Sanofi
BeiGene
Galvanize Therapeutics, Inc.
Cantargia AB
Eisai Inc.
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
Eli Lilly and Company
BioNTech SE
Novartis
Regeneron Pharmaceuticals
Eli Lilly and Company
Mereo BioPharma
Jiangsu HengRui Medicine Co., Ltd.